Radio-immuno-therapy (RIT)

Radiotherapy (RT) has the potential to sensitize tumors to immune checkpoint blockade (ICB) by promoting a T cell inflamed tumor microenvironment and has shown promising results in pre-clinical models of lung, bladder and head and neck cancers. This has led to the introduction of Radio-Immuno-Therapy (RIT) as a promising strategy for treatment of cancer.